OPK

OPK

USD

OPKO Health Inc. Common Stock

$1.410+0.040 (2.920%)

Prix en Temps Réel

Healthcare
Diagnostics & Research
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.370

Haut

$1.430

Bas

$1.370

Volume

2.69M

Fondamentaux de l'Entreprise

Capitalisation Boursière

1.1B

Industrie

Diagnostics & Research

Pays

United States

Statistiques de Trading

Volume Moyen

2.21M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $1.11Actuel $1.410Haut $2.04

Actualités Connexes

Analyst Upgrades

Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

Jefferies analyst Maury Raycroft downgrades OPKO Health from Buy to Hold and lowers the price target from $2 to $1.6.

Voir plus
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6
Analyst Upgrades

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

Barrington Research analyst Michael Petusky maintains OPKO Health with a Outperform and maintains $2.25 price target.

Voir plus
Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target
GlobeNewswire

OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) --

Voir plus
OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
GlobeNewswire

OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28,

Voir plus
OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
GlobeNewswire

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial

Voir plus
OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.